SynthesisArquivos brasileiros de cardiologia2018
Association Between Increased Levels of Cystatin C and the Development of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis.
Synthesis in Arquivos brasileiros de cardiologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis.Cardiology journal · 2025Pooled it
- Association between handgrip strength to Cystatin C ratio and hearing loss: insights from the CHARLS study.Journal of health, population, and nutrition · 2025Article
- Salivary small extracellular vesicles reveal protein signatures in young patients with coronary artery disease.Clinical proteomics · 2025Article
- Association of Serum Cystatin C with Stroke Morbidity and All-Cause and Cardio-Cerebrovascular Mortality: Evidence from the NHANES.Healthcare (Basel, Switzerland) · 2025Article
- Relationship between serum cystatin C and diabetic retinopathy in T2DM patients.Frontiers in medicine · 2025Article
- Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study.International journal of molecular sciences · 2024Article
- Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- No causal association between plasma cystatin C and cardiovascular diseases: Mendelian randomization analyses in UK biobank.Frontiers in medicine · 2023Article
- Prediction of Outcomes Through Cystatin C and cTnI in Elderly Type 2 Myocardial Infarction Patients.Clinical interventions in aging · 2023Article
- Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study.Scientific reports · 2022Article
- From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.International journal of molecular sciences · 2022Review
- Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.Journal of the American Heart Association · 2022Article
- Ageing-related markers and risks of cancer and cardiovascular disease: a prospective study in the EPIC-Heidelberg cohort.European journal of epidemiology · 2022Article
- Prognostic Value of Pretreatment Serum Cystatin C Level in Nasopharyngeal Carcinoma Patients in the Intensity-modulated Radiotherapy Era.OncoTargets and therapy · 2021Article
- Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality.Arquivos brasileiros de cardiologia · 2018Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystatin C seems promising for evaluating the risk of cardiovascular events and mortality.
objectiveTo evaluate the association between high levels of cystatin C and the development of cardiovascular events or mortality.
methodsThe articles were selected in the Medline/PubMed, Web of Science, and Scielo databases. The eligibility criteria were prospective cohort observational trials that assessed the association of high serum levels of cystatin C with the development of cardiovascular events or mortality in individuals with normal renal function. Only studies that evaluated the mortality outcome compared the fourth with the first quartile of cystatin C and performed multivariate Cox's proportional hazard regression analysis were included in the meta-analysis. A p value < 0,05 was considered significant.
resultsAmong the 647 articles found, 12 were included in the systematic review and two in the meta-analysis. The risk of development of adverse outcomes was assessed by eight studies using the hazard ratio. Among them, six studies found an increased risk of cardiovascular events or mortality. The multivariate regression analysis was performed by six studies, and the risk of developing adverse outcomes remained significant after the analysis in four of these studies. The result of the meta-analysis [HR = 2.28 (1.70-3.05), p < 0.001] indicated that there is a significant association between high levels of cystatin C and the risk of mortality in individuals with normal renal function.
conclusionThere is a significant association between high levels of cystatin C and the development of cardiovascular events or mortality in individuals with normal renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.